DRUGGING "UNDRUGGABLE" DISEASE-CAUSING PROTEINS: FOCUS ON SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) 3.
| Autor: | Tweardy DJ; HOUSTON, TEXAS. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Transactions of the American Clinical and Climatological Association [Trans Am Clin Climatol Assoc] 2022; Vol. 132, pp. 61-76. |
| Abstrakt: | Signal transducer and activator of transcription (STAT) 3 has been assigned to the group of "undruggable" disease-causing proteins, despite its containing a Src-homology (SH) 2 domain, a potential Achilles' heel that has eluded successful targeting by academic and pharmaceutical groups over the past 30 years. Based on mutational and modeling studies, our group developed a unique virtual ligand screening strategy targeting the STAT3 SH2 domain that was coupled to robust biochemical and cellular assays and structure-based medicinal chemistry and led to the identification of TTI-101. TTI-101 represents one of the most advanced, direct, small-molecule inhibitors of an SH2 domain-containing, disease-causing protein in clinical development. TTI-101 is currently being evaluated in a Phase 1 study to determine safety and tolerability in addition to pharmacodynamic effects and efficacy in patients with advanced solid tumors. Competing Interests: Potential Conflicts of Interest: David J. Tweardy co-founded and holds equity in Tvardi Therapeutics. The intellectual property used in the research supporting this publication was created by Dr. Tweardy and licensed to Tvardi Therapeutics, Inc. Dr. Tweardy also receives compensation from Tvardi as a member of its scientific advisory board. (© 2022 The American Clinical and Climatological Association.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|